Andrew Foderaro, MD
Pulmonary Disease · Providence, RINPI 1700179942
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (57.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 82.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $4,452 and has fallen 97.6% since, to $106 in 2025.
Across 24 payments — averaging $274.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Johnson & Johnson$756
- AstraZeneca$148
- Medtronic$106
- Regeneron Healthcare Solutions, Inc.$106
- Boehringer Ingelheim$28
What the payments were for
- Travel & lodging$2,00831%
- Food & beverage$80212%
- Education$3,77357%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $5,441 |
| Johnson & Johnson | 3 | $756 |
| AstraZeneca | 3 | $148 |
| Medtronic | 2 | $106 |
| Regeneron Healthcare Solutions, Inc. | 1 | $106 |
| Boehringer Ingelheim | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$2,265
- Monarch Platform$731
- FASENRA$125
- DUPIXENT$106
How this compares
$6,584 in reported general payments places this provider in the 85th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 230 | $162,730 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 162 | $74,937 |
| Breo ElliptaFluticasone/Vilanterol | 164 | $66,500 |
| Dupixent SyringeDupilumab | 17 | $63,178 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $6,914 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,090 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,877 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,639 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $5,584 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $4,686 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,410 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $4,038 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,536 |
| Ventolin HfaAlbuterol Sulfate | 39 | $2,169 |
| Montelukast Sodium | 56 | $539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $148 | $12,55330 claims |
| Boehringer IngelheimSpiriva Respimat | $28 | $5,87712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Providence
- Christopher MullinProvidence$19K
- Rabih El BizriProvidence$12K
- Joseph MehargProvidence$4K
- Linda NiciProvidence$3K
- Vesna BuntakProvidence$2K
- Ahmed EidProvidence$2K
- Anthony LubinskyProvidence$344
- Debasree BanerjeeProvidence$122
- Navneet SinghProvidence$96
- Jisoo LeeProvidence$89
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.